This page provides a timely snapshot of our most recent negotiation activity, including an overview of open files and updates on key milestones from the past 4 weeks.
How current is this information?
The content on this page is updated on an ongoing basis to reflect the most recent available information. Please note that updates about negotiation activity may take 1–2 weeks to be processed.
“Under consideration for negotiation” means we’re currently considering the evidence and gathering other information to inform the negotiation approach, including the drug’s eligibility for expedited negotiation pathways. Once negotiation activities are underway, the drug is in active negotiation.
Letters of engagement
We send letters of engagement (LOE) to manufacturers at the end of the consideration phase, to begin active negotiations. The drugs listed below have recently entered active negotiation.
| Brand name | Manufacturer | Indication | LOE date |
|---|---|---|---|
| Kevzara | Sanofi-Aventis Canada Inc. | For the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids, or who have experienced a relapse during corticosteroid taper. | 2026-09-02 |
| Kisqali | Novartis Pharmaceuticals Canada Inc. | in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II-III early breast cancer at high risk of recurrence- In pre- or perimenopausal women, or men, the aromatase inhibitor should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist. | 2026-08-21 |
| Xospata | Astellas Pharma Canada, Inc | For post-transplant maintenance for measurable residual disease (MRD) positive FLT3-ITD mutated acute myeloid leukemia (AML). | 2026-09-09 |
| Cablivi | Sanofi-Aventis Canada Inc. | For the treatment of adults with acquired thrombotic thrombocytopenic purpura in combination with plasma exchange and immunosuppressive therapy | 2026-09-03 |
| Empaveli | Sobi Canada Inc. | For the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy or primary immune-complex membranoproliferative lomerulonephritis to reduce proteinuria. | 2026-09-03 |
| Zoryve | Arcutis Biotherapeutics, Inc. | For the topical treatment of plaque psoriasis of the scalp and body in | 2026-09-02 |
| Amvuttra | Alnylam Netherlands B.V. | Cardiomyopathy due to transthyretin-mediated amyloidosis | 2026-08-18 |
| Imdelltra | Amgen Canada Inc. | For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy | 2025-06-05 |
| Fabhalta | Novartis Pharmaceuticals Canada Inc. | For the treatment of adult patients with C3 glomerulopathy (C3G) to reduce proteinuria | |
| Tolak | Actinic keratosis | 2026-09-09 | |
| Trimbow | Chronic Obstructive Pulmonary Disease (COPD) | 2026-09-02 | |
| Imdelltra (Active ENP) | Amgen Canada Inc. | for the treatment of adult patients with small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. | 2026-08-18 |
| Welireg (Active ENP) | Merck Canada Inc. | for treatment of adult and pediatric (12 years and older) patients with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) | 2026-09-02 |
Letters of intent
A letter of intent (LOI) outlines the negotiated terms of an agreement between the pCPA and a manufacturer at the end of a successful negotiation. The list below reflects our latest LOIs.
| Title | Manufacturer | Indication | LOE date | LOI date |
|---|---|---|---|---|
| Lynparza | AstraZeneca Canada Inc. | For the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated locally advanced unresectable or metastatic pancreatic adenocarcinoma whose disease has not progressed on prior systemic therapy | 2026-09-02 | 2026-09-02 |
| Voydeya | Alexion Pharma GmbH | As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal emoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH) | 2026-08-28 | 2026-08-28 |
| Maviret | AbbVie Corporation | For the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and pediatric patients 3 years of age and older and weighing ≥12 kg. | 2026-08-31 | 2026-08-31 |
Negotiations ended without agreement
Both negotiating parties strive to reach timely agreements. In rare cases, alignment between manufacturers and the pCPA can’t be reached. Each negotiation is unique, and decisions are made based on the information available at the time.
The pCPA always welcomes unsolicited offers, should a manufacturer want to re-engage and go back to the negotiation table.
When agreements can’t be reached, public drug plans may make decisions about providing coverage through their exceptional access programs.
| Title | Manufacturer | Indication | LOE date | Close date |
|---|---|---|---|---|
| Tecentriq | Hoffmann-La Roche Ltd. | For the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained greater than or equal to 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering greater than or equal to 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations. | 2026-05-25 | 2026-08-26 |
Negotiations that weren’t pursued - Last 4 weeks
We don’t pursue negotiations in cases where the drug’s health technology assessment (HTA) recommendations were negative or “do not reimburse.” Other reasons, such as the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected on the drug’s page in the database.
There have been no negotiations which pCPA decided not to pursue in the last four weeks